RT @ericdeinmd: #EULAR2022 LB002 P3 Double-Blind W/d study: Baricitinib for JIA âï¸All pts start in open label w good
Tweet Content
#EULAR2022 LB002
P3 Double-Blind W/d study: Baricitinib for JIA
⭐️All pts start in open label w good benefit (1/2 with ACR70)
⭐️PBO W/d led to 50% flare vs 17% in BARI group, flares earlier
@RheumNow https://t.co/apSSLqu1mp
Show on Archive Page
On
Display in Search Results
On
PDQ
Off